{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:13:47Z","timestamp":1777493627170,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s11064-017-2216-x","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T03:37:12Z","timestamp":1489030632000},"page":"1972-1982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide"],"prefix":"10.1007","volume":"42","author":[{"given":"David","family":"Bibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz","family":"Mawasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H.","family":"Finnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","volume":"78","author":"MS Brodie","year":"2012","unstructured":"Brodie MS, Barry SE, Bamagous GA, Norrie JD, Kwan, Pattern P (2012) Treatment response to newly diagnosed epilepsy. Neurology 78:1548\u20131554","journal-title":"Neurology"},{"key":"2216_CR2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","volume":"46","author":"RS Fisher","year":"2005","unstructured":"Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J Jr (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470\u2013472","journal-title":"Epilepsia"},{"key":"2216_CR3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","volume":"6","author":"E Perucca","year":"2007","unstructured":"Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6:793\u2013804","journal-title":"Lancet Neurol"},{"key":"2216_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","volume":"9","author":"M Bialer","year":"2010","unstructured":"Bialer M, White HS (2010) Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nature Rev Drug Discov 9:68\u201383.","journal-title":"Nature Rev Drug Discov"},{"key":"2216_CR5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","volume":"111","author":"M Bialer","year":"2015","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2015) Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 111:85\u2013141","journal-title":"Epilepsy Res"},{"key":"2216_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13634","author":"M Bialer","year":"2017","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2017) Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference (EILAT XIII). Epilepsia. doi: 10.1111\/epi.13634","journal-title":"Epilepsia"},{"key":"2216_CR7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","volume":"4","author":"M Bialer","year":"2007","unstructured":"Bialer M, Yagen B (2007) Valproic acid: second generation. Neurother 4:130\u2013137","journal-title":"Neurother"},{"key":"2216_CR8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0272-0590(86)90180-6","volume":"6","author":"H Nau","year":"1986","unstructured":"Nau H, Loscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fundam Appl Toxicol 6:669\u2013676","journal-title":"Fundam Appl Toxicol"},{"key":"2216_CR9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/tx950216s","volume":"9","author":"U Bojic","year":"1996","unstructured":"Bojic U, Elmazar MM, Hauck RS, Nau H (1996) Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 9:866\u2013870","journal-title":"Chem Res Toxicol"},{"key":"2216_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1528-1157.1994.tb02939.x","volume":"35","author":"MJ Liu","year":"1994","unstructured":"Liu MJ, Pollack GM (1994) Pharmacokinetics and pharmacodynamics of valproate analogues in rats. IV. Anticonvulsant action and neurotoxicity of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid. Epilepsia 35:234\u2013243","journal-title":"Epilepsia"},{"key":"2216_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0028-3908(85)90028-0","volume":"24","author":"W Loscher","year":"1985","unstructured":"Loscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 24:427\u2013435","journal-title":"Neuropharmacology"},{"key":"2216_CR12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","volume":"64","author":"M Bialer","year":"2012","unstructured":"Bialer M (2012) Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 64:887\u2013895","journal-title":"Adv Drug Deliv Rev"},{"key":"2216_CR13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/brain\/awv325","volume":"139","author":"P Chang","year":"2016","unstructured":"Chang P, Augustin K, Boddum K, Williams S, Sun M, Terschak JA, Hardege JD, Chen PE, Walker MC, Williams RS (2016) Seizure control by decanoic acid through direst AMPA receptor inhibition. Brain 139:431\u2013443","journal-title":"Brain"},{"key":"2216_CR14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/brain\/awv369","volume":"139","author":"MA Rogawski","year":"2016","unstructured":"Rogawski MA (2016) A fatty acid in MCT ketogenic diet for epilepsy treatment blocks AMPA receptors. Brain 139:306\u2013309","journal-title":"Brain"},{"key":"2216_CR15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0028-3908(83)90134-X","volume":"22","author":"PE Keane","year":"1983","unstructured":"Keane PE, Simiand J, Mendes E, Santucci V, Morre M (1983) The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice. Neuropharmacology 22:875\u2013879","journal-title":"Neuropharmacology"},{"issue":"Suppl 1","key":"2216_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1984.tb05637.x","volume":"25","author":"M Morre","year":"1984","unstructured":"Morre M, Keane PE, Vernieres JC, Simiand J, Roncucci R (1984) Valproate: recent findings and perspectives. Epilepsia 25(Suppl 1):5\u20139","journal-title":"Epilepsia"},{"key":"2216_CR17","first-page":"969","volume-title":"Antiepileptic Drugs","author":"ASR Resor","year":"1995","unstructured":"Resor A SR, Resor LD, Woodbury DM, Kemp JW (1995) Acetazolamide. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic Drugs, 4th\u00a0edn, Raven Press, New York, pp\u00a0969\u2013985.","edition":"4"},{"key":"2216_CR18","first-page":"1331","volume":"28","author":"AJ Ganz","year":"1978","unstructured":"Ganz AJ, Waser PG, Pfirrmann RW (1978) Development of new antiepileptics. V. Pharmacological activity of some derivatives of sulfanilamide (author\u2019s transl). Arzneimittelforschung 28:1331\u20131334","journal-title":"Arzneimittelforschung"},{"key":"2216_CR19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm0109199","volume":"45","author":"B Masereel","year":"2002","unstructured":"Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT (2002) Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem 45:312\u2013320","journal-title":"J Med Chem"},{"key":"2216_CR20","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.bmc.2004.05.003","volume":"12","author":"SM Tasso","year":"2004","unstructured":"Tasso SM, Moon S, Bruno-Blanch LE, Estiu GL (2004) Characterization of the anticonvulsant profile of valpromide derivatives. Bioorg Med Chem 12:3857\u20133869","journal-title":"Bioorg Med Chem"},{"key":"2216_CR21","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1021\/jm100170w","volume":"53","author":"N Hen","year":"2010","unstructured":"Hen N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B (2010) Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-amino-benzensulfonamide. J Med Chem 53:4177\u20134186","journal-title":"J Med Chem"},{"key":"2216_CR22","first-page":"578","volume-title":"Medicinal chemistry","author":"WJ Murray","year":"1977","unstructured":"Murray WJ, Kier LB (1977) Noncyclic anticonvulsants. In: Vida JA (ed) Medicinal chemistry. Academic Press, New York, pp\u00a0578\u2013619"},{"key":"2216_CR23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/jm00303a029","volume":"12","author":"BJ Ludwing","year":"1969","unstructured":"Ludwing BJ, Powell LS, Berger FM (1969) Carbamate derivatives related to meprobamate. J Med Chem 12:462\u2013472","journal-title":"J Med Chem"},{"key":"2216_CR24","first-page":"301","volume-title":"Antiepileptic drugs","author":"JM Pellock","year":"2002","unstructured":"Pellock JM, Perhach JM, Sofia RD (2002) Felbamate. In: Levy RH, Mattson RH, Meldrum BS, m Perucca E (eds) Antiepileptic drugs, 5th\u00a0edn, Lippincott, Wiliams & Wilkinss, Philadelphia, 301\u2013318.","edition":"5"},{"key":"2216_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","volume":"83","author":"M Bialer","year":"2009","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83:1\u201343","journal-title":"Epilepsy Res"},{"key":"2216_CR26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","volume":"92","author":"M Bialer","year":"2010","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92:89\u2013124","journal-title":"Epilepsy Res"},{"issue":"16","key":"2216_CR27","first-page":"P2","volume":"86","author":"G Karauss","year":"2016","unstructured":"Karauss G, French J, Kamin J, Ilankumaran P (2016) Seizure freedom with YKP3089 as adjunctive therapy for refractory partial-onset seizures in double-llind placebo-controlled trials. Neurology 86(16) P2\u2013019","journal-title":"Neurology"},{"key":"2216_CR28","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1021\/jm201751x","volume":"55","author":"N Hen","year":"2012","unstructured":"Hen N, Bialer M, Yagen B (2012) Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. J Med Chem 55:2835\u20132845","journal-title":"J Med Chem"},{"key":"2216_CR29","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/epi.12857","volume":"55","author":"T Shekh-Ahmad","year":"2014","unstructured":"Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Bialer M (2014) Enantioselective pharmacodynamic and pharmacokinetic analysis of two active chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 55:1944\u20131952","journal-title":"Epilepsia"},{"key":"2216_CR30","unstructured":"White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH (2002) Discovery and preclinical development. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds), Antiepileptic drugs, 5th\u00a0edn, Lippincott Williams & Wilkins, New York, pp\u00a036\u201348."},{"key":"2216_CR31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nurt.2006.11.009","volume":"4","author":"M Smith","year":"2007","unstructured":"Smith M, Wilcox KS, White HS (2007) Discovery of antiepileptic drugs. Neurother 4:12\u201317","journal-title":"Neurother"},{"key":"2216_CR32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/tera.1420380403","volume":"38","author":"RH Finnell","year":"1988","unstructured":"Finnell RH, Bennett GD, Karras SB, Mohl VK (1988) Common hierarchies of susceptibility to the induction of neural tube defects by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 38:313\u2013320","journal-title":"Teratology"},{"key":"2216_CR33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.0.CO;2-Z","volume":"45","author":"BC Wlodarczyk","year":"1996","unstructured":"Wlodarczyk BC, Craig JC, Bennett GD, Calvin JA, Finnell RH (1996) Valproic acid\u2013induced changes in gene expression during neurulation in a mouse model. Teratology 45:284\u2013297","journal-title":"Teratology"},{"key":"2216_CR34","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","volume":"246","author":"RG Khalifah","year":"1971","unstructured":"Khalifah RG (1971) The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 246:2561\u20132573","journal-title":"J Biol Chem"},{"key":"2216_CR35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0960-894X(03)00029-5","volume":"13","author":"A Casini","year":"2003","unstructured":"Casini A, Antel J, Abbate F, Scozzafava A, David S, Waldeck H, Schafer S, Supuran CT (2003) Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates\/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. 13:841\u2013845","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"2216_CR36","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.bmcl.2005.03.032","volume":"15","author":"G Simone De","year":"2005","unstructured":"De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT (2005) Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett 15:2315\u20132320","journal-title":"Bioorg Med Chem Lett"},{"key":"2216_CR37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/jm901524f","volume":"53","author":"C Temperini","year":"2010","unstructured":"Temperini C, Innocenti A, Scozzafava A, Parkkila S, Supuran CT (2010) The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example. J Med Chem 53:850\u2013854","journal-title":"J Med Chem"},{"key":"2216_CR38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov 7:168\u2013181","journal-title":"Nature Rev Drug Discov"},{"key":"2216_CR39","first-page":"141","volume-title":"General nervous system penetration of drugs: importance of phisicochemical properties","author":"SG Jezequel","year":"1992","unstructured":"Jezequel SG (1992) General nervous system penetration of drugs: importance of phisicochemical properties, Taylor & Francis London, pp\u00a0141\u2013178."},{"key":"2216_CR40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1528-1167.2011.03338.x","volume":"53","author":"HS White","year":"2012","unstructured":"White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmed T, Wilcox KS, McDonough JH, Stables JP, Kaufmann D, Yagen B, Bialer M (2012) A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 53:134\u2013146","journal-title":"Epilepsia"},{"key":"2216_CR41","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1021\/jm00017a024","volume":"38","author":"J Palaty","year":"1995","unstructured":"Palaty J, Abbott FS (1995) Starcuture activity relestions of unsaturated nalpoogs use of valrproic acid. J Med Chem 38:3398\u20133406","journal-title":"J Med Chem"},{"key":"2216_CR42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/jps.2600821214","volume":"82","author":"MMA Elamzar","year":"1993","unstructured":"Elamzar MMA, Hauck RS, Nau H (1993) Anticonvuslnat and neurotoxic activities of twelve anlaogues of valproic acid. J Pharm Sci 82:1255\u20131258","journal-title":"J Pharm Sci"},{"key":"2216_CR43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuint.2005.08.007","volume":"48","author":"P Halmi","year":"2006","unstructured":"Halmi P, Parkkila S, Honkaniemi J (2006) Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus. Neurochem Int 48:24\u201330","journal-title":"Neurochem Int"},{"key":"2216_CR44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2015.1066675","volume":"15","author":"CT Supuran","year":"2015","unstructured":"Supuran CT (2015) Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 15:851\u2013856","journal-title":"Expert Rev Neurother"},{"key":"2216_CR45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/156802607780636726","volume":"7","author":"A Thiry","year":"2007","unstructured":"Thiry A, Dogn\u00e8 JM, Masereel B, Supuran CT (2007) Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 7:855\u2013864","journal-title":"Curr Top Med Chem"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-017-2216-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-017-2216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T18:39:56Z","timestamp":1658774396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-017-2216-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s11064-017-2216-x","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}